Francesco Ditonno, Alberto Bianchi, Sarah Malandra, Antonio Benito Porcaro, Emanuela Fantinel, Riccardo Negrelli, Matteo Ferro, Michele Milella, Matteo Brunelli, Riccardo Autorino, Maria Angela Cerruto, Alessandro Veccia, Alessandro Antonelli
Poly (ADP-ribose) polymerase inhibitors (PARPi) represent an option in selected cases of metastatic castration-resistant prostate cancer (mCRPC). The aim of the present systematic review and meta-analysis is to evaluate the efficacy and safety of approved (Olaparib, Rucaparib) and investigational (Talazoparib, Niraparib, Veliparib) PARPi in mCRPC patients. Three databases were queried for studies analyzing oncological outcomes and adverse events of mCRPC patients receiving PARPi. Primary outcome was a PSA decline ≥ 50% from baseline...
December 21, 2023: Clinical Genitourinary Cancer